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BACKGROUND
The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–
glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, 
is undefined.
METHODS
We randomly assigned patients with type 2 diabetes who had or were at risk for ath-
erosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The pri-
mary safety outcome was a composite of major adverse cardiovascular events (MACE), 
defined as cardiovascular death, myocardial infarction, or ischemic stroke. The pri-
mary efficacy outcomes were MACE and a composite of cardiovascular death or hos-
pitalization for heart failure. Secondary efficacy outcomes were a renal composite 
(≥40% decrease in estimated glomerular filtration rate to <60 ml per minute per 
1.73 m2 of body-surface area, new end-stage renal disease, or death from renal or 
cardiovascular causes) and death from any cause.
RESULTS
We evaluated 17,160 patients, including 10,186 without atherosclerotic cardiovascular 
disease, who were followed for a median of 4.2 years. In the primary safety outcome 
analysis, dapagliflozin met the prespecified criterion for noninferiority to placebo with 
respect to MACE (upper boundary of the 95% confidence interval [CI], <1.3; P<0.001 
for noninferiority). In the two primary efficacy analyses, dapagliflozin did not result 
in a lower rate of MACE (8.8% in the dapagliflozin group and 9.4% in the placebo 
group; hazard ratio, 0.93; 95% CI, 0.84 to 1.03; P = 0.17) but did result in a lower rate 
of cardiovascular death or hospitalization for heart failure (4.9% vs. 5.8%; hazard 
ratio, 0.83; 95% CI, 0.73 to 0.95; P = 0.005), which reflected a lower rate of hospi-
talization for heart failure (hazard ratio, 0.73; 95% CI, 0.61 to 0.88); there was no 
between-group difference in cardiovascular death (hazard ratio, 0.98; 95% CI, 0.82 to 
1.17). A renal event occurred in 4.3% in the dapagliflozin group and in 5.6% in the 
placebo group (hazard ratio, 0.76; 95% CI, 0.67 to 0.87), and death from any cause 
occurred in 6.2% and 6.6%, respectively (hazard ratio, 0.93; 95% CI, 0.82 to 1.04). Dia-
betic ketoacidosis was more common with dapagliflozin than with placebo (0.3% 
vs. 0.1%, P = 0.02), as was the rate of genital infections that led to discontinuation of the 
regimen or that were considered to be serious adverse events (0.9% vs. 0.1%, P<0.001).
CONCLUSIONS
In patients with type 2 diabetes who had or were at risk for atherosclerotic cardio-
vascular disease, treatment with dapagliflozin did not result in a higher or lower rate 
of MACE than placebo but did result in a lower rate of cardiovascular death or hos-
pitalization for heart failure, a finding that reflects a lower rate of hospitalization 
for heart failure. (Funded by AstraZeneca; DECLARE–TIMI 58 ClinicalTrials.gov 
number, NCT01730534.)
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Diabetes mellitus is estimated to affect more than 415 million adults world-wide. The prevalence is increasing, and it 
is expected that more than 640 million adults 
will have diabetes by 2040.1 Patients with diabetes 
are at high risk for adverse outcomes from ath-
erosclerotic cardiovascular disease,2,3 heart fail-
ure,4 and renal disease.5 The high risk of heart 
failure in patients with diabetes is independent 
of coronary disease, and limited data are available 
to guide treatments for the prevention of heart 
failure.6,7 As a result of this intersection of diabe-
tes, atherosclerotic cardiovascular disease, and 
heart failure, the importance of determining 
diabetes therapies that are not only safe but also 
effective in reducing cardiovascular risk is para-
mount.8-10
Dapagliflozin is a selective inhibitor of sodium–
glucose cotransporter 2 (SGLT2) that blocks glu-
cose resorption in the proximal tubule of the 
kidney and promotes glucosuria.11-13 Other SGLT2 
inhibitors have shown favorable cardiovascular 
effects, including a reduction in the risk of hos-
pitalization for heart failure, predominantly in 
patients with type 2 diabetes and established 
cardiovascular disease14-16; they have also been 
shown to delay the progression of kidney dis-
ease.14,15,17-19 The Dapagliflozin Effect on Cardio-
vascular Events–Thrombolysis in Myocardial In-
farction 58 (DECLARE–TIMI 58) trial evaluated 
the effects of dapagliflozin on cardiovascular and 
renal outcomes in a broad population of patients 
who had or were at risk for atherosclerotic cardio-
vascular disease.
Me thods
Trial Design and Oversight
The DECLARE–TIMI 58 trial was a randomized, 
double-blind, multinational, placebo-controlled, 
phase 3 trial of dapagliflozin in patients with 
type 2 diabetes and established atherosclerotic 
cardiovascular disease or multiple risk factors for 
atherosclerotic cardiovascular disease.20,21 The 
trial was designed collaboratively by the Throm-
bolysis in Myocardial Infarction (TIMI) Study 
Group, the Hadassah Medical Organization, the 
trial executive committee (see Section A in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org, for members of 
these groups), and the sponsor (AstraZeneca) 
and was conducted at 882 sites in 33 countries. 
The trial protocol, available at NEJM.org, was 
approved by the institutional review board at 
each participating site, and all participants pro-
vided written informed consent. The complete, 
raw database was provided to the TIMI Study 
Group, which independently conducted all anal-
yses reported in this article. The executive com-
mittee made the decision to submit the manu-
script for publication. The first author wrote the 
first draft of the manuscript, and all the authors 
participated in revisions. The authors vouch for 
the accuracy and completeness of the data and 
analyses and for the fidelity of the trial to the 
protocol and the statistical analysis plan.
As described previously,20 the trial was origi-
nally designed with a primary safety outcome of 
major adverse cardiovascular events (MACE), in 
accordance with Food and Drug Administration 
(FDA) guidelines.10 However, during the trial, 
compelling external scientific information from 
the EMPA-REG OUTCOME trial, which evaluat-
ed another SGLT2 inhibitor, showed greater 
benefit with respect to cardiovascular death and 
hospitalization for heart failure than with respect 
to MACE.14 In response, and before the data and 
safety monitoring committee of our trial viewed 
data on MACE, the trial executive committee 
amended the protocol to include two primary 
efficacy outcomes: MACE and cardiovascular 
death or hospitalization for heart failure. The 
two outcomes would split an alpha level equally, 
and no change would be made in the primary 
safety outcome or the sample size. The decision 
was made by the executive committee without 
knowledge of any blinded or unblinded com-
parative data on MACE. This change was com-
municated to regulators, and the protocol was 
updated and approved by the appropriate institu-
tional review boards. The description of statisti-
cal methods herein reflects this change (addi-
tional details are provided in Section B in the 
Supplementary Appendix). Investigators and par-
ticipants were informed of the positive results of 
the EMPA-REG OUTCOME trial, and participants 
signed a revised informed consent document to 
continue participation.
Trial Population
Eligible patients were 40 years of age or older 
and had type 2 diabetes, a glycated hemoglobin 
level of at least 6.5% but less than 12.0%, and a 
creatinine clearance of 60 ml or more per min-
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ute. Eligible patients also had multiple risk fac-
tors for atherosclerotic cardiovascular disease or 
had established atherosclerotic cardiovascular dis-
ease (defined as clinically evident ischemic heart 
disease, ischemic cerebrovascular disease, or pe-
ripheral artery disease). Participants with multiple 
risk factors were men 55 years of age or older or 
women 60 years of age or older who had one or 
more traditional risk factors, including hyper-
tension, dyslipidemia (defined as a low-density 
lipoprotein cholesterol level >130 mg per deciliter 
[3.36 mmol per liter] or the use of lipid-lowering 
therapies), or use of tobacco. A complete list of 
eligibility criteria is provided in Section C in the 
Supplementary Appendix.20
Trial Procedures
Eligible patients were enrolled in a 4-to-8-week, 
single-blind run-in period during which all pa-
tients received placebo, and blood and urine test-
ing was performed. Patients who remained eligi-
ble after the run-in period were randomly assigned 
in a 1:1 ratio, in a double-blind fashion, to re-
ceive 10 mg of dapagliflozin daily or matching 
placebo. The use of other glucose-lowering agents 
(other than an open-label SGLT2 inhibitor, pio-
glitazone, or rosiglitazone) was at the discretion 
of the treating physician. Patients were to return 
for in-person follow-up every 6 months until trial 
completion for laboratory testing and assessment 
of clinical and safety events and adherence to 
the trial regimen. Patients were contacted by tele-
phone every 3 months between in-person visits.
Outcomes
The primary safety outcome was MACE (defined 
as cardiovascular death, myocardial infarction, or 
ischemic stroke). The two primary efficacy out-
comes were MACE and a composite of cardiovas-
cular death or hospitalization for heart failure. 
Two secondary efficacy outcomes were prespeci-
fied. The first was a renal composite outcome, 
defined as a sustained decrease of 40% or more 
in estimated glomerular filtration rate (eGFR) — 
calculated by means of the Chronic Kidney Dis-
ease Epidemiology Collaboration equation22 — 
to less than 60 ml per minute per 1.73 m2 of 
body-surface area, new end-stage renal disease, 
or death from renal or cardiovascular causes. The 
other secondary outcome was death from any 
cause. A prespecified additional renal composite 
outcome included all the criteria described for 
the secondary renal outcome except for cardiovas-
cular death. Serious adverse events and adverse 
events leading to discontinuation of dapagliflozin 
or placebo were collected comprehensively, as 
described in Section B in the Supplementary Ap-
pendix. The clinical-events committee of the 
TIMI Study Group adjudicated all components of 
the primary outcomes and key components of 
other safety and efficacy outcomes (Section D in 
the Supplementary Appendix).23
Statistical Analysis
Safety was assessed first in an analysis of the 
noninferiority of dapagliflozin to placebo with 
respect to MACE. In accordance with FDA guide-
lines,10 noninferiority would be shown if the up-
per boundary of the two-sided 95% confidence 
interval of the hazard ratio for MACE was less 
than 1.3, at a one-sided alpha level of 0.023 (af-
ter adjustment for two interim analyses). If non-
inferiority of dapagliflozin to placebo was con-
firmed, then the two efficacy outcomes of MACE 
and the composite of cardiovascular death or 
hospitalization for heart failure were to be tested 
in parallel, each at a two-sided alpha level of 0.023. 
If either was significant, the alpha value could be 
recycled24 to test the other efficacy outcome at a 
two-sided alpha level of 0.046. If after this proce-
dure both efficacy outcomes were significant, 
the secondary outcomes were to be tested, at a 
two-sided alpha level of 0.046, in a hierarchical 
fashion.20
In the original design of the trial, we deter-
mined that approximately 17,150 patients would 
need to be enrolled to accrue at least 1390 events, 
with a minimum follow-up period of 3 years. This 
event number was calculated to provide the trial 
with 85% power to show a 15% lower rate of 
MACE in the dapagliflozin group than in the 
placebo group, at a two-sided alpha level of 0.046, 
and to provide more than 99% power to show the 
noninferiority of dapagliflozin to placebo with 
respect to MACE. Details about the effects on the 
power calculation of the addition of cardiovascu-
lar death or hospitalization for heart failure as a 
primary efficacy outcome are provided in Section 
B in the Supplementary Appendix.
The primary analyses of cardiovascular safety 
and efficacy were performed with data from 17,160 
patients who underwent randomization, with the 
exclusion of 30 participants from one site; data 
from patients at that site were excluded because 
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of serious Good Clinical Practice violations in 
another trial that created uncertainty about the 
integrity of the data. Analyses were performed 
according to the intention-to-treat principle with 
the use of adjudicated events. Hazard ratios, 95% 
confidence intervals, and P values for time-to-
event analyses are reported for the primary out-
comes and were derived from a Cox proportion-
al-hazards model in the overall population; all 
analyses were stratified according to baseline 
atherosclerotic cardiovascular disease category 
(established atherosclerotic cardiovascular dis-
ease or multiple risk factors for atherosclerotic 
cardiovascular disease) and the presence or ab-
sence of hematuria at baseline. After the MACE 
safety analysis, other safety assessments were 
performed in a safety analysis population (which 
consisted of patients who received at least one 
dose of dapagliflozin or placebo). Safety events 
are reported with P values without adjustment 
for multiple testing.
R esult s
Patients, Trial Regimen, and Follow-up
During the run-in phase, we enrolled 25,698 
patients. A total of 17,160 participants complet-
ed the run-in phase and were eligible to undergo 
randomization, including 6974 patients (40.6%) 
with established atherosclerotic cardiovascular 
disease and 10,186 (59.4%) with multiple risk 
factors for atherosclerotic cardiovascular dis-
ease. Patients were followed for a median of 4.2 
years (interquartile range, 3.9 to 4.4), for a total 
of 69,547 patient-years of follow-up. A total of 
3962 patients discontinued the trial regimen pre-
maturely, at a rate of 5.7% per year, including 
1811 of 8574 patients (21.1%) in the dapagliflozin 
group and 2151 of 8569 (25.1%) in the placebo 
group. Rates of withdrawal of consent (224 pa-
tients, at a rate of 0.3% per year) and loss to 
follow-up (30 patients, at a rate of <0.1% per year) 
were low and did not differ between the two 
groups (Fig. S1 in the Supplementary Appendix).
Baseline characteristics of the patients were 
balanced between the groups (Table 1). The mean 
(±SD) glycated hemoglobin level was 8.3±1.2%, 
and the median duration of diabetes was 11.0 years 
(interquartile range, 6.0 to 16.0). The mean eGFR 
was 85.2 ml per minute per 1.73 m2; 45% of 
patients had an eGFR between 60 and 90 ml per 
minute per 1.73 m2. As a result of the exclusion 
criterion for creatinine clearance at screening, 
only a small percentage (7%) of patients had an 
eGFR of less than 60 ml per minute per 1.73 m2 
at randomization. Before trial entry, 10% of pa-
tients had a history of heart failure.
Effect on Cardiovascular Risk Factors
Dapagliflozin had favorable effects on several 
cardiovascular risk factors (Fig. S2 in the Supple-
mentary Appendix). Patients in the dapagliflozin 
group had lower glycated hemoglobin levels 
throughout the trial than patients in the placebo 
group (average least-squares mean absolute dif-
ference between the groups, 0.42%; 95% confi-
dence interval [CI], 0.40 to 0.45). During the trial, 
9.5% of the patients in the dapagliflozin group 
and 11.4% in the placebo group received treatment 
with glucagon-like protein receptor agonists, and 
3.4% and 6.1%, respectively, received treatment 
with open-label SGLT2 inhibitors. The least-squares 
mean difference between the groups in the re-
duction in weight during the trial was 1.8 kg 
(95% CI, 1.7 to 2.0), the difference in the reduc-
tion in systolic blood pressure was 2.7 mm Hg 
(95% CI, 2.4 to 3.0), and the difference in the re-
duction in diastolic blood pressure was 0.7 mm Hg 
(95% CI, 0.6 to 0.9). All reductions were greater 
with dapagliflozin.
Cardiovascular and Renal Outcomes
Dapagliflozin met the prespecified criterion for 
noninferiority with respect to MACE (upper bound-
ary of the 95% CI, <1.3; P<0.001 for noninferiority). 
With respect to efficacy, dapagliflozin resulted in 
a lower rate of cardiovascular death or hospital-
ization for heart failure than placebo (4.9% vs. 
5.8%; hazard ratio, 0.83; 95% CI, 0.73 to 0.95; 
P = 0.005) (Fig. 1). It should be noted that the 
lower rate of the composite outcome of cardio-
vascular death or hospitalization for heart failure 
in the dapagliflozin group than in the placebo 
group was due to a lower rate of hospitalization 
for heart failure in the dapagliflozin group (haz-
ard ratio, 0.73; 95% CI, 0.61 to 0.88); there was 
no difference between the groups in the rate of 
cardiovascular death (hazard ratio, 0.98; 95% CI, 
0.82 to 1.17) (Fig. 2). In addition, this efficacy of 
dapagliflozin with respect to the rate of cardio-
vascular death or hospitalization for heart fail-
ure was similar in the subgroup of patients with 
established atherosclerotic cardiovascular disease 
(7.8% in the dapagliflozin group and 9.3% in the 
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placebo group; hazard ratio, 0.83; 95% CI, 0.71 
to 0.98) and in the subgroup of patients with 
multiple risk factors (2.8% in the dapagliflozin 
group and 3.4% in the placebo group; hazard 
ratio, 0.84; 95% CI, 0.67 to 1.04; P = 0.99 for in-
teraction) (Fig. 3). Dapagliflozin did not result in 
a lower rate of MACE than placebo (8.8% and 
9.4% in the two groups, respectively; hazard ra-
Characteristic
Dapagliflozin 
(N = 8582)
Placebo 
(N = 8578)
Age — yr 63.9±6.8 64.0±6.8
Female sex — no. (%) 3171 (36.9) 3251 (37.9)
Race — no. (%)†
White 6843 (79.7) 6810 (79.4)
Black 295 (3.4) 308 (3.6)
Asian 1148 (13.4) 1155 (13.5)
Other 296 (3.4) 305 (3.6)
Region — no. (%)
North America 2737 (31.9) 2731 (31.8)
Europe 3806 (44.3) 3823 (44.6)
Latin America 946 (11.0) 931 (10.9)
Asia–Pacific 1093 (12.7) 1093 (12.7)
Body‑mass index‡ 32.1±6.0 32.0±6.1
Median duration of type 2 diabetes (IQR) — yr 11.0 (6.0–16.0) 10.0 (6.0–16.0)
Glycated hemoglobin — % 8.3±1.2 8.3±1.2
Systolic blood pressure — mm Hg 135.1±15.3 134.8±15.5
Estimated glomerular filtration rate — ml/min/1.73 m2 85.4±15.8 85.1±16.0
Established atherosclerotic cardiovascular disease — no. (%) 3474 (40.5) 3500 (40.8)
History of coronary artery disease — no. (%) 2824 (32.9) 2834 (33.0)
History of peripheral artery disease — no. (%) 522 (6.1) 503 (5.9)
History of cerebrovascular disease — no. (%) 653 (7.6) 648 (7.6)
History of heart failure — no. (%) 852 (9.9) 872 (10.2)
Glucose‑lowering therapies — no. (%)
Insulin 3567 (41.6) 3446 (40.2)
Metformin 7020 (81.8) 7048 (82.2)
Sulfonylurea 3615 (42.1) 3707 (43.2)
DPP‑4 1418 (16.5) 1470 (17.1)
GLP‑1 receptor agonist 397 (4.6) 353 (4.1)
Cardiovascular therapies — no. (%)
Antiplatelet agents 5245 (61.1) 5242 (61.1)
ACE inhibitor or ARB 6977 (81.3) 6973 (81.3)
Beta‑blocker 4498 (52.4) 4532 (52.8)
Statin or ezetimibe 6432 (74.9) 6436 (75.0)
Diuretics 3488 (40.6) 3479 (40.6)
*  Plus–minus values are means ±SD. There were no significant differences between the groups in the characteristics at 
baseline. Percentages may not total 100 because of rounding. ACE denotes angiotensin‑converting enzyme, ARB angio‑
tensin‑receptor blocker, DPP‑4 dipeptidyl peptidase 4, GLP‑1 glucagon‑like peptide 1, and IQR interquartile range.
†  Race was reported by the patient.
‡  The body‑mass index is the weight in kilograms divided by the square of the height in meters.
Table 1. Baseline Characteristics of the Patients.*
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tio, 0.93; 95% CI, 0.84 to 1.03; P = 0.17) (Fig. 1). 
Among patients with established atherosclerotic 
cardiovascular disease, the rate of MACE was 
13.9% in the dapagliflozin group and 15.3% in 
the placebo group (hazard ratio, 0.90; 95% CI, 
0.79 to 1.02); among patients with multiple risk 
factors, the rate was 5.3% and 5.2%, respectively 
(hazard ratio, 1.01; 95% CI, 0.86 to 1.20; P = 0.25 
for interaction). Comparisons of individual com-
ponents of the composite outcomes are shown 
in Figure 2. Sensitivity analyses of the primary 
safety and efficacy outcomes with the use of 
competing-risk and per-protocol approaches did 
not materially affect any of the estimates (Table S2 
in the Supplementary Appendix).
Because dapagliflozin resulted in a significantly 
lower rate of cardiovascular death and hospitaliza-
tion for heart failure than placebo but did not 
result in a significantly lower rate of MACE, analy-
ses of additional outcomes are hypothesis-gener-
Figure 1. Major Cardiovascular and Renal Outcomes and Death from Any Cause.
Shown is the cumulative incidence of the two primary efficacy outcomes of cardiovascular death or hospitalization for heart failure  
(Panel A) and major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke 
(Panel B). Dapagliflozin was noninferior to placebo with respect to the primary safety outcome of MACE (upper boundary of the 95% CI, 
<1.3; P<0.001 for noninferiority). Also shown is the cumulative incidence of the secondary efficacy outcomes of a renal composite 
(≥40% decrease in estimated glomerular filtration rate to <60 ml per minute per 1.73 m2 of body‑surface area, new end‑stage renal dis‑
ease, or death from renal or cardiovascular causes) (Panel C) and death from any cause (Panel D). The inset in each panel shows the 
same data on an enlarged y axis.
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ating. In the overall population, the incidence of 
the renal composite outcome was 4.3% in the 
dapagliflozin group and 5.6% in the placebo group 
(hazard ratio, 0.76; 95% CI, 0.67 to 0.87). The rate 
of death from any cause did not differ signifi-
cantly between the groups (6.2% in the dapa-
gliflozin group and 6.6% in the placebo group; 
hazard ratio, 0.93; 95% CI, 0.82 to 1.04) (Fig. 1).
Major subgroup analyses were performed ac-
cording to risk group (established atheroscle-
rotic cardiovascular disease or risk factors for 
atherosclerotic cardiovascular disease), history of 
heart failure (yes or no), and eGFR (≥90, ≥60 to 
<90, and <60 ml per minute per 1.73 m2) (Fig. 3). 
Other subgroups of interest are shown in Figure S3 
in the Supplementary Appendix. The benefit of 
dapagliflozin with respect to cardiovascular death 
or hospitalization for heart failure tended to be 
similar across subgroups. Additional component 
outcomes in key subgroups are shown in Figures 
S4 through S6 in the Supplementary Appendix.
Additional Safety Assessments
Key safety results are provided in Table 2, and in 
Table S3 in the Supplementary Appendix. Fewer 
patients in the dapagliflozin group than in the 
placebo group discontinued the assigned regi-
men during the course of the trial, and fewer 
patients in the dapagliflozin group reported a 
serious adverse event or had major hypoglycemia 
(see the Supplementary Appendix), acute kidney 
injury, or bladder cancer. The rates of amputa-
tion, fracture, volume depletion, and hypersensi-
tivity were balanced between the groups. Diabetic 
ketoacidosis was more common in the dapa-
gliflozin group than in the placebo group (0.3% 
vs. 0.1%; hazard ratio, 2.18; 95% CI, 1.10 to 4.30; 
P = 0.02). More than 80% of patients with dia-
betic ketoacidosis were using insulin at baseline. 
Genital infections that led to discontinuation of 
the trial regimen or were considered to be seri-
ous adverse events were more common in the 
dapagliflozin group than in the placebo group 
(0.9% vs. 0.1%; hazard ratio, 8.36; 95% CI, 4.19 
to 16.68; P<0.001), both in men and in women, 
although genital infections reported as serious 
adverse events were rare (two events in each 
group). Six cases of Fournier’s gangrene were re-
ported, one in the dapagliflozin group and five in 
the placebo group.
Figure 2. Key Efficacy Outcomes and Their Components.
Two‑sided P values are shown for the two primary efficacy outcomes of cardiovascular death or hospitalization for heart failure and 
MACE. The abbreviation eGFR denotes estimated glomerular filtration rate, and ESRD end‑stage renal disease.
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Discussion
DECLARE–TIMI 58 was a large trial that as-
sessed cardiovascular outcomes with the SGLT2 
inhibitor dapagliflozin. It involved more than 
17,000 patients who were followed for a median 
of 4.2 years; over the course of the trial, more 
than 1500 patients had MACE and 900 died 
from cardiovascular causes or were hospitalized 
for heart failure. This trial included more than 
10,000 patients without evident atherosclerotic 
cardiovascular disease, a population for which 
definitive data on the effects of SGLT2 inhibitors 
were previously lacking.
There are several key findings from the 
DECLARE–TIMI 58 trial. In a broad population 
of patients with type 2 diabetes who were at 
high risk for cardiovascular events, dapagliflozin 
was noninferior to placebo with respect to the 
composite safety outcome of cardiovascular death, 
myocardial infarction, or ischemic stroke (MACE), 
but it did not result in a significantly lower rate 
of MACE than placebo. Dapagliflozin did result 
in a lower rate of the other prespecified primary 
Figure 3. Major Subgroup Analyses of the Primary Efficacy Outcomes.
The two primary efficacy outcomes were a composite of cardiovascular death or hospitalization for heart failure and 
MACE. ASCVD denotes atherosclerotic cardiovascular disease, and MRF multiple risk factors with no evidence of 
ASCVD.
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efficacy outcome (the composite of cardiovascu-
lar death or hospitalization for heart failure), 
which reflected a lower rate of hospitalization for 
heart failure.
The lower rate of cardiovascular death or hos-
pitalization for heart failure in the dapagliflozin 
group than in the placebo group was consistent 
across multiple subgroups, which shows that 
dapagliflozin prevented cardiovascular events, 
particularly hospitalization for heart failure, in a 
broad range of patients, regardless of a history 
of atherosclerotic cardiovascular disease or heart 
failure. The majority of patients did not have a 
history of heart failure, so the prevention of new 
clinical heart failure is notable. Ongoing trials 
will assess the effects of dapagliflozin in dedi-
cated populations of patients with heart failure. 
Likewise, a consistent pattern of lower rates of 
progression of renal disease was seen among 
patients with and those without established ath-
erosclerotic cardiovascular disease, heart failure, 
or chronic kidney disease at baseline.
On the basis of results from previous tri-
als,8,9,25,26 current international guidelines for the 
management of diabetes25 have focused on the 
use of SGLT2 inhibitors in patients with athero-
sclerotic cardiovascular disease. These new data 
suggest that in patients without established ath-
erosclerotic cardiovascular disease, SGLT2 inhibi-
tion can prevent serious clinical events, particu-
larly hospitalization for heart failure, and possibly 
reduce the likelihood of progression of renal 
disease.
The DECLARE–TIMI 58 trial also adds sub-
stantially to the literature on current safety con-
cerns for this class of drugs, which are based on 
relatively sparse previous data. There have been 
conflicting reports of a possible increased risk 
of stroke, amputation, and fractures with vari-
ous SGLT2 inhibitors.14,15,27,28 We saw no evi-
dence, despite focused collection of events, of a 
higher risk of stroke, amputations, or fractures 
with dapagliflozin than with placebo. Likewise, 
despite the observation of an excess of cases of 
bladder cancer in earlier, smaller studies of 
dapagliflozin, we observed a lower rate of blad-
der cancer with dapagliflozin than with placebo. 
The rate of diabetic ketoacidosis was higher in 
the dapagliflozin group than in the placebo 
group, a finding consistent with observations in 
Event
Dapagliflozin 
(N = 8574)
Placebo 
(N = 8569)
Hazard Ratio 
(95% CI) P Value
no. (%)
Serious adverse event 2925 (34.1) 3100 (36.2) 0.91 (0.87–0.96) <0.001
Adverse event leading to discontinuation 
of trial regimen
693 (8.1) 592 (6.9) 1.15 (1.03–1.28) 0.01
Major hypoglycemic event 58 (0.7) 83 (1.0) 0.68 (0.49–0.95) 0.02
Diabetic ketoacidosis 27 (0.3) 12 (0.1) 2.18 (1.10–4.30) 0.02
Amputation 123 (1.4) 113 (1.3) 1.09 (0.84–1.40) 0.53
Fracture 457 (5.3) 440 (5.1) 1.04 (0.91–1.18) 0.59
Symptoms of volume depletion 213 (2.5) 207 (2.4) 1.00 (0.83–1.21) 0.99
Acute kidney injury 125 (1.5) 175 (2.0) 0.69 (0.55–0.87) 0.002
Genital infection 76 (0.9) 9 (0.1) 8.36 (4.19–16.68) <0.001
Urinary tract infection 127 (1.5) 133 (1.6) 0.93 (0.73–1.18) 0.54
Cancer 481 (5.6) 486 (5.7) 0.99 (0.87–1.12) 0.83
Bladder cancer 26 (0.3) 45 (0.5) 0.57 (0.35–0.93) 0.02
Breast cancer 36 (0.4) 35 (0.4) 1.02 (0.64–1.63) 0.92
Hypersensitivity 32 (0.4) 36 (0.4) 0.87 (0.54–1.40) 0.57
Hepatic event 82 (1.0) 87 (1.0) 0.92 (0.68–1.25) 0.60
*  Additional details, data sources, and a complete list of serious adverse events are provided in the Supplementary 
Appendix. P values and 95% confidence intervals have not been adjusted for multiple comparisons.
Table 2. Safety Events.*
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studies of other SGLT2 inhibitors15,29; the excess 
rate was less than 0.1% per year. The rate of genital 
infections was higher with dapagliflozin than 
with placebo, but the rate of Fournier’s gangrene 
was not.
In the context of previous cardiovascular out-
comes trials with empagliflozin and canagliflozin, 
the DECLARE–TIMI 58 trial supports clear pat-
terns of effect. First, SGLT2 inhibitors have a 
more robust and consistent effect on the preven-
tion of heart failure and renal outcomes than on 
atherosclerotic cardiovascular events. These ob-
servations fit with the mechanism of action of 
SGLT2 inhibitors on the kidney and the well-
documented downstream effects, including na-
triuresis, blood-pressure reduction, improved tu-
bular glomerular feedback, vascular compliance, 
and endothelial function.15,30-33 Second, although 
treatment with SGLT2 inhibitors appears to re-
sult in a moderate reduction in the risk of MACE 
in patients with atherosclerotic cardiovascular 
disease, no effect has been observed in patients 
with multiple risk factors for atherosclerotic 
cardiovascular disease.15 This observation is dis-
tinct from the robust data from multiple trials 
that show reductions in the risk of heart failure 
and renal outcomes regardless of patient charac-
teristics.
We did not find that SGLT2 inhibition with 
dapagliflozin resulted in a lower rate of cardio-
vascular death or death from any cause than 
placebo, a finding that contrasts with that in the 
EMPA-REG OUTCOME trial. Although we can-
not discount that there are differences among 
the specific drugs in the class, there are other 
possible explanations. There were important dif-
ferences in the design of the trials, including a 
more restrictive exclusion of patients according 
to creatinine clearance in our trial (patients with 
a creatinine clearance <60 ml per minute were 
not eligible), which could have contributed to 
this distinction. Because SGLT2 inhibitors act in 
the kidney, and because in other trials patients 
with chronic kidney disease are a population 
that seemed to have greater benefits with SGLT2 
inhibitors than other populations, it is possible 
that excluding these patients may have limited a 
mortality benefit.34,35 Overall mortality rates in 
the placebo group were lower in the current trial 
than in the EMPA-REG OUTCOME trial, which 
highlights possible differences among popula-
tions. Finally, it is possible that the lack of ben-
efit with respect to cardiovascular death was due 
to chance, since the confidence intervals around 
the estimate are wide.
The trial outcomes were modified in re-
sponse to external data that pointed to the pre-
vention of hospitalization for heart failure as a 
major benefit of SGLT2 inhibitors. These adapta-
tions, which were made in accordance with the 
principles of adaptive trial design,36 were not 
based on knowledge of any blinded or unblinded 
comparative data on MACE in the trial. They 
were made before the data and safety monitor-
ing board performed efficacy analyses, and trial 
participants, ethics committees, and regulators 
were appropriately notified. Although the change 
resulted in a positive result for the primary out-
come of cardiovascular death or hospitalization 
for heart failure, splitting the alpha without in-
creasing the sample size could have resulted in 
lower statistical power for the trial.
This trial included a broad population of pa-
tients with and those without atherosclerotic 
cardiovascular disease. It is possible that some 
patients may have had undiagnosed atheroscle-
rotic cardiovascular disease or heart failure. Given 
the adherence requirement in the placebo run-in 
period, patients who found it difficult to adhere 
to the regimen may have withdrawn from the 
trial before randomization.
The DECLARE–TIMI 58 trial showed that the 
SGLT2 inhibitor dapagliflozin was noninferior 
to placebo with respect to the primary safety 
outcome of MACE. Dapagliflozin did not result 
in a significantly lower rate of MACE, but in a 
broad population of patients with type 2 diabe-
tes it did result in a significantly lower rate of 
cardiovascular death or hospitalization for heart 
failure than placebo, with additional findings 
supporting a possible lower rate of adverse renal 
outcomes.
A data sharing statement provided by the authors is available 
with the full text of this article at NEJM.org.
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